GRFS News and Press, Grifols S.A. From 02/27/24

Grifols S.A. (GRFS) is expected to report $0.22 for Q4 2023

2024-02-21 12:51:10 ET More on Grifols S.A. Grifols: Wait And See For Now Grifols: I've Read The Short-Seller Report, And I Mostly Disagree Grifols Is Building Momentum Grifols appoints new CEO; founding family members to leave executive roles Grifols...

2024-02-09 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-09 16:51:46 ET Gainers: Amtech Systems ( ASYS ) +7% . Oportun Financial ( OPRT ) +5% . Nutanix ( NTNX ) +3% . Gritstone bio ( GRTS ) +2% . Grifols ( GRFS ) +2% . Losers: Applied Blockchain ( APLD ) -10% . ...

2024-02-05 14:20:46 ET More on Grifols Grifols: Wait And See For Now Grifols: I've Read The Short-Seller Report, And I Mostly Disagree Grifols Is Building Momentum Grifols’ banking exposure under ECB scrutiny: Reuters ELAB, KIND and RLX among p...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...

SAN FRANCISCO, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Grifols, S.A. (NASDAQ: GRFS) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/grfs Contact An Attorney Now: GRFS@hbsslaw.com 844-916-08...

2024-01-17 14:56:12 ET More on Grifols S.A. Grifols: Wait And See For Now Grifols: I've Read The Short-Seller Report, And I Mostly Disagree Grifols Is Building Momentum ELAB, KIND and RLX among pre-market losers Haier Group still looking to buy Shangh...

2024-01-17 09:00:32 ET Losers: DatChat DATS -32% plans to sell shares through public offering . Acurx Pharmaceuticals ( NASDAQ: ACXP ) -24% announces positive comparative Microbiology and Microbiome data for Ibezapolstat from phase 2b clinical trial in CDI ...

2024-01-15 03:28:37 ET Spanish plasma therapeutics company Grifols ( NASDAQ: GRFS ) said on Sunday Haier Group still plans to close the acquisition of a 20% stake in Shanghai RAAS Blood Products amid speculations on the $1.8B deal. In December 2023, Grifols ( GRFS ) announ...